Calendario›SNY›CANDID
CANDID
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
Ensayo de Sanofi en Moderate to Severe Atopic Dermatitis (del registro, en inglés).
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 305
- Centros
- 30
- Fin del objetivo primario
- abr 2026
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en oct 2023.
Qué mide
Percentage of participants achieving a reduction in Eczema Area and Severity Index (EASI) of at least 75% at 6 months (del registro, en inglés) (mes 6)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is a prospective, 18-month observational study of adult, adolescent and pediatric Canadian participants with Atopic Dermatitis (AD) commonly known as Eczema, who receive treatment with Dupixent for moderate-to-severe AD (msAD) according to the Canadian-specific prescribing information (in accordance with the Canadian Dupixent Product Monograph). The study will be conducted in approximately 30 centers in Canada to assess participants of all ethnicities and races. At each participating site, all AD participants who receive an initial prescription for Dupixent will be invited to participate in this study, until the Canadian enrollment goal is achieved.
Más ensayos de SNY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Avalglucosidase alfa · Mini-COMET | Fase 2 | En marcha, sin reclutar | sep 2019 (real) |
| Yellow fever vaccine | Fase 2 | En marcha, sin reclutar | may 2022 (real) |
| Yellow fever vaccine · VYF02 | Fase 2 | En marcha, sin reclutar | jun 2022 (real) |
| SAR441344 IV | Fase 2 | En marcha, sin reclutar | sep 2022 (real) |
| Meningococcal Polysaccharide | Fase 3 | En marcha, sin reclutar | mar 2023 (real) |
| Isatuximab IV · IRAKLIA | Fase 3 | En marcha, sin reclutar | nov 2024 (real) |
Todos los de SNY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06099704), actualizada en may 2026.